Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
On April 9, 2025, a groundbreaking study published in Cell introduced a novel delivery technology called ENVLPE (Engineered Nucleocytosolic Vehicles for Loading of Programmable Editors), developed by a team of scientists from the Helmholtz Munich Center and the Technical University of Munich.
Adenoviruses have long been a popular viral vector for gene therapy because they are able to affect both replicating and non-replicating cells, accommodate large transgenes, and encode proteins without integrating into the host cell genome. More specifically, they are used as vectors to load recombinant DNA or protein therapeutics for targeted therapy by infecting targeted cells.
There are two main production platforms for gamma-retroviral and lentiviral vectors: transient processes, which involve transfection of plasmids (multiple or single) into appropriate cell lines, and stable processes, which involve the preparation of stable cell lines that produce viral vectors using packaging cell lines that express packaging and envelope genes.
Advances in genetic engineering methods have enabled the development of effective gene therapy approaches for a variety of diseases based on adeno-associated viruses (AAVs). AAVs can be effectively used to treat a wide range of inherited and acquired human diseases, more specifically monogenic inherited diseases, i.e. diseases caused by mutations in one gene.
As highly structured protein particles, VLPs are conducive to the uptake of antigen-presenting cells and can stimulate the host's innate and adaptive immune response functions. In the past three decades, VLPs have been widely used, especially in the field of vaccines. Some VLP-based vaccines have been used in commercial production or have entered different stages of clinical research.
Copyright © 2026 Creative Biogene. All rights reserved.